Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

Sponsor
Peking University First Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05683353
Collaborator
(none)
60
1
6.5
9.2

Study Details

Study Description

Brief Summary

The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.

Condition or Disease Intervention/Treatment Phase
  • Other: None intervention

Detailed Description

To establish a retrospective and prospective cohort of patients with hematologic tumors infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2. Firstly, peripheral blood samples will be collected at infection time points and after SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome sequencing and immunological experiments will be performed to analyze the differentially expressed genes, immune function of cells, etc.

Comparative analysis:
  1. To compare the immune function of patients with hematologic tumors and those without underlying diseases after infection with SARS-CoV-2.

  2. The transcriptomic and proteomic changes of patients with hematologic tumors are compared with those without underlying diseases after infection with SARS-CoV-2.

  3. From the perspective of complex (human protein interaction subnetwork), the dynamic change process of SARS-CoV-2-targeted human protein complex (periodic complex) was deeply explored, in order to further analyze its potential dynamic infection mechanism and provide new clues for the discovery of drug targets.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets
Actual Study Start Date :
Dec 14, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients with SARS-CoV-2 positive hematologic tumors

Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems.

Other: None intervention
None intervention.

People with SARS-CoV-2 positive without underlying diseases

People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems.

Other: None intervention
None intervention.

Outcome Measures

Primary Outcome Measures

  1. Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors [1 year]

    To compare the infection mechanism and immune function of patients with hematologic tumors infected with SARS-CoV-2 and people infected with SARS-CoV-2 without underlying diseases.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection
Exclusion Criteria:
  • Severe diseases associated with other systems

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University First Hospital Beijing Beijing China 100034

Sponsors and Collaborators

  • Peking University First Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yujun DONG, chief of department of hematology, Peking University First Hospital
ClinicalTrials.gov Identifier:
NCT05683353
Other Study ID Numbers:
  • PekingUFH_
First Posted:
Jan 13, 2023
Last Update Posted:
Jan 17, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yujun DONG, chief of department of hematology, Peking University First Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 17, 2023